Conestoga Capital Advisors LLC Sells 285,517 Shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT)

Conestoga Capital Advisors LLC cut its holdings in LeMaitre Vascular, Inc. (NASDAQ:LMAT - Free Report) by 14.4% during the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 1,692,834 shares of the medical instruments supplier's stock after selling 285,517 shares during the period. LeMaitre Vascular makes up approximately 2.1% of Conestoga Capital Advisors LLC's investment portfolio, making the stock its 17th largest position. Conestoga Capital Advisors LLC owned about 7.53% of LeMaitre Vascular worth $155,978,000 at the end of the most recent quarter.

A number of other hedge funds have also bought and sold shares of the business. Copeland Capital Management LLC increased its holdings in shares of LeMaitre Vascular by 0.7% during the fourth quarter. Copeland Capital Management LLC now owns 1,172,015 shares of the medical instruments supplier's stock worth $107,990,000 after purchasing an additional 8,623 shares during the period. Pacer Advisors Inc. grew its position in LeMaitre Vascular by 8.4% during the fourth quarter. Pacer Advisors Inc. now owns 2,950 shares of the medical instruments supplier's stock worth $272,000 after buying an additional 228 shares in the last quarter. KBC Group NV increased its stake in LeMaitre Vascular by 58.4% during the 4th quarter. KBC Group NV now owns 1,112 shares of the medical instruments supplier's stock worth $102,000 after acquiring an additional 410 shares during the period. Linden Thomas Advisory Services LLC lifted its position in shares of LeMaitre Vascular by 5.6% during the 4th quarter. Linden Thomas Advisory Services LLC now owns 34,482 shares of the medical instruments supplier's stock valued at $3,177,000 after acquiring an additional 1,834 shares during the period. Finally, SG Americas Securities LLC bought a new position in shares of LeMaitre Vascular in the fourth quarter worth $158,000. 84.64% of the stock is owned by institutional investors.

LeMaitre Vascular Trading Up 1.3 %

LMAT traded up $1.30 on Thursday, reaching $99.83. The stock had a trading volume of 159,466 shares, compared to its average volume of 146,240. The company has a market capitalization of $2.24 billion, a price-to-earnings ratio of 54.55, a price-to-earnings-growth ratio of 2.13 and a beta of 0.96. LeMaitre Vascular, Inc. has a fifty-two week low of $58.41 and a fifty-two week high of $109.58. The firm has a 50-day moving average of $96.87 and a 200-day moving average of $93.13.

Insider Buying and Selling

In related news, Director Bridget A. Ross sold 3,750 shares of the company's stock in a transaction that occurred on Friday, November 15th. The stock was sold at an average price of $101.47, for a total value of $380,512.50. Following the sale, the director now directly owns 2,278 shares in the company, valued at $231,148.66. This represents a 62.21 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. 10.79% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

Several equities research analysts recently weighed in on LMAT shares. Barrington Research upped their price objective on shares of LeMaitre Vascular from $92.00 to $93.00 and gave the stock an "outperform" rating in a research report on Friday, November 1st. Cantor Fitzgerald assumed coverage on shares of LeMaitre Vascular in a research note on Tuesday, October 15th. They issued a "neutral" rating and a $96.00 price objective on the stock. Oppenheimer reaffirmed an "outperform" rating and issued a $93.00 target price (up previously from $90.00) on shares of LeMaitre Vascular in a report on Friday, November 1st. Finally, StockNews.com cut LeMaitre Vascular from a "buy" rating to a "hold" rating in a report on Friday, December 13th. Three research analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the company has an average rating of "Moderate Buy" and an average price target of $94.57.

LeMaitre Vascular Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.